IL17A and metabolic dysfunction-associated steatotic liver disease: Our findings of an increased and active expression of γΔ T cells in NASH patients corroborate previous findings and may highlight a potential therapeutic approach to blocking the progression of SS to NASH and eventually to NAFLD, via blocking or eliminating IL-17A-producing γΔ T cells.